Delta-Radiomics Predicts Response to First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients with Liver Metastases

SIMPLE SUMMARY: Oxaliplatin-based chemotherapy remains the mainstay of first-line therapy in patients with metastatic colorectal cancer (mCRC). Unfortunately, only approximately 60% of treated patients achieve response, and half of responders will experience an early onset of disease progression. Fu...

Descripción completa

Detalles Bibliográficos
Autores principales: Giannini, Valentina, Pusceddu, Laura, Defeudis, Arianna, Nicoletti, Giulia, Cappello, Giovanni, Mazzetti, Simone, Sartore-Bianchi, Andrea, Siena, Salvatore, Vanzulli, Angelo, Rizzetto, Francesco, Fenocchio, Elisabetta, Lazzari, Luca, Bardelli, Alberto, Marsoni, Silvia, Regge, Daniele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750408/
https://www.ncbi.nlm.nih.gov/pubmed/35008405
http://dx.doi.org/10.3390/cancers14010241

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8750408/
https://www.ncbi.nlm.nih.gov/pubmed/35008405
http://dx.doi.org/10.3390/cancers14010241

Ejemplares similares